Provided by Tiger Trade Technology Pte. Ltd.

Sight Sciences, Inc.

8.26
+0.11001.35%
Post-market: 8.260.00000.00%19:30 EDT
Volume:180.59K
Turnover:1.49M
Market Cap:455.03M
PE:-14.85
High:8.35
Open:8.25
Low:8.05
Close:8.15
52wk High:9.24
52wk Low:3.19
Shares:55.09M
Float Shares:37.29M
Volume Ratio:0.52
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5564
EPS(LYR):-0.7369
ROE:-48.42%
ROA:-10.84%
PB:8.60
PE(LYR):-11.21

Loading ...

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

GlobeNewswire
·
Apr 02

Sight Sciences to present at Needham Healthcare Conference fireside chat

Reuters
·
Mar 31

BRIEF-Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021

Reuters
·
Mar 30

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)

TIPRANKS
·
Mar 30

Sight Sciences Wins Key Patent Ruling in Glaucoma Case

TIPRANKS
·
Mar 30

Sight Sciences: Order Awarded Ongoing Royalty of 10% of Hydrus Revenue Through Nov 10, 2028

THOMSON REUTERS
·
Mar 30

Sight Sciences: Order Awarded Monetary Damages of $34 Mln, Plus Supplemental Damages & Interest, for Past Infringement

THOMSON REUTERS
·
Mar 30

Sight Sciences: Order on Post-Trial Motions Preserves Jury's Verdict and Awards Monetary Damages to Co

THOMSON REUTERS
·
Mar 30

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

GlobeNewswire
·
Mar 30

Sight Sciences price target lowered to $5 from $6.50 at Citi

TIPRANKS
·
Mar 11

Sight Sciences Earnings Call Highlights Disciplined Growth

TIPRANKS
·
Mar 08

Sight Sciences Is Maintained at Neutral by Citigroup

Dow Jones
·
Mar 07

Stifel Nicolaus Sticks to Their Buy Rating for Sight Sciences (SGHT)

TIPRANKS
·
Mar 05

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Keros Therapeutics (KROS) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Mar 05

Sight Sciences Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
Mar 05

Sight Sciences Q4 revenue rises 7%

Reuters
·
Mar 05

Sight Sciences reports Q4 EPS (8c), consensus (14c)

TIPRANKS
·
Mar 05

BRIEF-Sight Sciences Q4 Revenue USD 20.4 Million Vs. IBES Estimate USD 20.4 Million

Reuters
·
Mar 05

Sight Sciences Inc - Guides FY2026 Revenue $82 Mln-$88 Mln

THOMSON REUTERS
·
Mar 05

Sight Sciences Q4 Gross Margin 87%

THOMSON REUTERS
·
Mar 05